In-silico and Literature-Based Perspectives of Astragalin as a Multi-Target Therapeutic Agent for Alzheimer’s
Letters in Applied NanoBioScience · 30.06.2026 · 15 (2)
DOI: 10.33263/lianbs152.052 ↗Kurz gefasst
Fachartikel in der Zeitschrift Letters in Applied NanoBioScience, online erschienen am 30.06.2026. Verfasst von Anish Singh und 3 weiteren Autor:innen. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease is a progressive neurodegenerative disorder characterized by the accumulation of Aβ plaques and tau protein neurofibrillary tangles, along with oxidative stress, chronic neuroinflammation, and progressive cognitive decline. A class of polyphenolic compounds, flavonoids, known for their anti-inflammatory and antioxidant properties, has shown promise in mitigating Alzheimer’s disease pathology. Among them, the flavonoid glycoside astragalin (kaempferol-3-O-glucoside), found in plants such as Astragalus membranaceus and Morus alba, exhibits strong neuroprotective effects. It reduces neuroinflammation by inhibiting microglial activation and lowering pro-inflammatory cytokine levels, while its antioxidant activity protects neurons from Aβ-induced oxidative damage. Preclinical studies suggest that astragalin enhances mitochondrial function, reduces oxidative stress, and attenuates Aβ-induced neuroinflammation. The structure of astragalin was retrieved from the PubChem database and energy-minimized using Chem3D. The crystal structures of the target proteins were obtained from the protein data bank (PDB) and prepared by removing water molecules and adding polar hydrogens using AutoDock tools. Molecular docking was performed, employing a grid-based algorithm and standard scoring functions to predict binding affinities and key residue interactions. Visualization and 2D/3D interaction mapping were conducted using Discovery Studio Visualizer. Molecular docking studies further support its therapeutic potential: astragalin shows favorable binding affinity with Nrf-2, potentially activating antioxidant response elements; it interacts with Aβ (PDB ID: 1IYT) shows binding energy -30.8 kcal/mol, possibly stabilizing non-toxic conformations and preventing aggregation; and it binds within the ligand-binding domain of ERα (PDB ID: 1A52) shows binding energy -7.7 kcal/mol, suggesting a modulatory role in estrogen-mediated neuroprotection. It also interacts with Tau protein (Tau, PDB ID: 2mz7), which shows binding energy -29.9 kcal/mol, and NF-κB (PDB ID: 1NFK)shows binding energy -6.8 kcal/mol, suggesting a modulatory role in alzheimer’s disease. These interactions, along with astragalin’s ability to cross the blood-brain barrier and modulate key signaling pathways such as PI3K/AKT-mTOR, underscore its promise as a multi-targeted agent for future Alzheimer’s disease therapies.
Zitieren
APA
Singh, A., Dalal, D., Sharma, R., & Singh, L. (2026). In-silico and Literature-Based Perspectives of Astragalin as a Multi-Target Therapeutic Agent for Alzheimer’s. Letters in Applied NanoBioScience, 15(2). https://doi.org/10.33263/lianbs152.052
Vancouver
Singh A, Dalal D, Sharma R, Singh L. In-silico and Literature-Based Perspectives of Astragalin as a Multi-Target Therapeutic Agent for Alzheimer’s. Letters in Applied NanoBioScience. 2026;15(2). doi:10.33263/lianbs152.052
BibTeX
@article{Singh2026,
author = {Singh, Anish and Dalal, Diksha and Sharma, Rajiv and Singh, Lovedeep},
title = {In-silico and Literature-Based Perspectives of Astragalin as a Multi-Target Therapeutic Agent for Alzheimer’s},
journal = {Letters in Applied NanoBioScience},
year = {2026},
volume = {15},
number = {2},
doi = {10.33263/lianbs152.052}
}
EUVIMED